What Is AREDS2? My Practical Guide to the Eye Health Formula

When I first started looking seriously into nutritional supplements for eye health, AREDS2 was one of those terms that appeared almost everywhere. It showed up on supplement bottles, in discussions about macular degeneration, and in recommendations from eye-care professionals. At first glance, it sounds like the name of a vitamin blend. In reality, AREDS2 represents something considerably more important: a major clinical research program that helped establish a specific nutritional approach for certain people with age-related macular degeneration.

What makes AREDS2 especially interesting to me is that it sits in a very different category from the typical supplement marketed simply for “better eyesight.” The formula grew out of large, federally supported clinical trials conducted to answer a specific medical question: could particular nutrients help slow the progression of age-related macular degeneration, commonly called AMD, in people who were already at substantial risk of the disease becoming more advanced? The answer was nuanced, but important enough that AREDS2 supplements are still widely discussed in ophthalmology today.

In this guide, I want to explain what AREDS2 is, what is actually in the formula, who may benefit from it, what the clinical research found, and what its limitations are. I will also discuss how other eye-support supplements, including products such as Retina Clear, fit into the bigger picture. My goal is not to portray any supplement as a miracle treatment, but to separate well-established research from marketing language so that the subject becomes much easier to understand.

What Is AREDS2?

AREDS2 stands for the Age-Related Eye Disease Study 2. It was a large clinical trial sponsored by the National Eye Institute, which is part of the U.S. National Institutes of Health. The study followed an earlier project known simply as AREDS, or the Age-Related Eye Disease Study. Both studies investigated whether high-dose combinations of particular vitamins, antioxidants, minerals, and other nutrients could influence the progression of AMD and other age-related eye conditions.

Today, people often use the term “AREDS2” in two slightly different ways. Technically, it refers to the clinical study. In everyday conversation, however, AREDS2 often refers to the nutritional supplement formula that developed from the research. When I see a bottle labeled “AREDS2 formula,” I therefore look for the nutrient combination associated with the National Eye Institute’s findings rather than assuming that AREDS2 is a particular brand. Several manufacturers sell products based on this formula.

The crucial point is that AREDS2 was developed around AMD rather than ordinary vision enhancement. It was not designed to make healthy eyes suddenly see more sharply, reverse routine nearsightedness, eliminate the need for glasses, or protect everybody from ever developing macular degeneration. The National Eye Institute states that AREDS and AREDS2 supplements benefited people with intermediate or late AMD but did not demonstrate the same benefit for people without AMD or those with early AMD.

Why Researchers Developed the AREDS2 Study

To understand why AREDS2 matters, I find it helpful to start with AMD itself. Age-related macular degeneration affects the macula, the specialized central portion of the retina responsible for the detailed vision we rely on for reading, recognizing faces, driving, and performing many precise visual tasks. AMD does not affect everyone in exactly the same way, and the disease can progress through different stages over many years.

The original AREDS trial enrolled thousands of participants and evaluated high doses of antioxidant vitamins and zinc. Researchers found that among participants at higher risk of progression, particularly those with intermediate AMD or advanced AMD in one eye, the combination of antioxidants and zinc could reduce the risk of progression to advanced AMD by roughly 25% over about five years. That was a meaningful finding because it demonstrated that nutritional supplementation could influence the course of AMD in a defined group of patients.

But the original formula raised additional questions. It contained beta-carotene, for example, which became problematic because beta-carotene supplementation had been associated with increased lung-cancer risk among smokers. Researchers were also interested in lutein and zeaxanthin, two carotenoids naturally concentrated in the macula, as well as omega-3 fatty acids. AREDS2 was therefore designed partly to determine whether lutein and zeaxanthin could improve the original approach and provide a safer alternative to beta-carotene.

What Is Inside the AREDS2 Formula?

When I evaluate an AREDS2 supplement, I do not judge it simply by seeing “eye health” written across the bottle. The amounts of the ingredients matter. One of the biggest misunderstandings around AREDS2 is assuming that any multivitamin containing lutein, zinc, vitamin C, and vitamin E is essentially the same thing. It is not. The clinical research involved specific nutrient amounts that are substantially higher than those found in many ordinary daily multivitamins.

The standard AREDS2 formulation commonly referenced by the National Eye Institute contains 500 mg vitamin C, 400 IU vitamin E, 10 mg lutein, 2 mg zeaxanthin, 80 mg zinc, and 2 mg copper. Copper was included because prolonged high-dose zinc supplementation can interfere with copper status. Unlike the original AREDS formula, AREDS2 substitutes lutein and zeaxanthin for beta-carotene.

The following is the one comparison I find most useful because it shows how the original AREDS formula evolved into the commonly recognized AREDS2 version.

One detail I always pay attention to is zinc. AREDS2 also investigated a lower-zinc version containing 25 mg instead of 80 mg. The trial did not establish a clear difference in AMD progression between the lower- and higher-zinc versions, but the traditional National Eye Institute reference formula continues to list 80 mg zinc. That is one reason I would not automatically assume that every product displaying “AREDS2” on its packaging has precisely the same formula; reading the Supplement Facts panel is still important.

How AREDS2 Is Thought to Support the Macula

The biological reasoning behind AREDS2 is tied partly to oxidative stress. The retina is a metabolically active tissue exposed continuously to light and oxygen. Over time, oxidative processes are among the factors researchers have investigated in relation to retinal aging. Vitamins C and E function as antioxidants, which is one reason they became part of the nutritional strategy studied in AREDS.

Lutein and zeaxanthin are particularly interesting because they naturally accumulate in the macular region of the retina. Together with another carotenoid called meso-zeaxanthin, they contribute to macular pigment. Research has shown that supplementation with lutein and zeaxanthin can increase their concentrations in the body and influence macular pigment measurements, although increasing macular pigment should not automatically be interpreted as curing AMD or improving vision in every individual.

Zinc has a different role. It is an essential mineral involved in numerous enzymes and biological functions, and the retina contains substantial concentrations of zinc. The original AREDS research provided the clinical reason for including zinc in the formula. What I find important here is that AREDS2 should be viewed as a clinically studied combination rather than a collection of independently miraculous ingredients. Its usefulness comes primarily from evidence surrounding the complete nutritional strategy in appropriate AMD populations.

What Did the AREDS2 Clinical Trial Actually Find?

AREDS2 was a substantial clinical study. Researchers enrolled 4,203 participants between the ages of 50 and 85 who were considered at risk of progression to advanced AMD. Participants generally had large drusen in both eyes or advanced AMD in one eye with significant disease in the other. The study was conducted through 82 clinical centers and followed participants for a median period of approximately five years.

One of the most misunderstood findings is that simply adding lutein and zeaxanthin to the original formula did not produce a statistically significant additional reduction in advanced AMD progression in the study’s primary analysis. Omega-3 DHA and EPA supplementation also did not provide the hoped-for additional reduction in the primary outcome. However, secondary analyses helped establish an important advantage of lutein and zeaxanthin: they could replace beta-carotene without sacrificing the overall nutritional strategy, while avoiding the beta-carotene concern for smokers and former smokers.

That distinction matters because AREDS2 is sometimes marketed as though scientists discovered that lutein and zeaxanthin alone dramatically stop macular degeneration. That is not an accurate summary of the study. The research was considerably more nuanced. The strongest practical lesson is that the modified AREDS nutritional formulation remains useful for appropriately selected people with AMD, while lutein and zeaxanthin offer advantages over beta-carotene, particularly from a safety perspective for people with a history of smoking.

Who May Benefit From AREDS2?

This is the section I consider most important because taking a clinically studied supplement only makes sense if the person taking it resembles the population in which the benefit was demonstrated. According to the National Eye Institute, AREDS2 supplements are generally relevant to people with intermediate AMD in one or both eyes or late AMD in one eye. An eye doctor can determine the stage of AMD through a comprehensive eye examination and retinal evaluation.

AREDS2 is not considered a proven preventive supplement for everybody simply because they are getting older. The National Eye Institute specifically explains that the clinical trials did not show a benefit for people who had no AMD or only early AMD. This is something I think should be made much clearer in conversations about eye supplements because many consumers encounter AREDS2 on a store shelf before they have ever had their macula examined.

A few practical points are especially worth remembering:

• Intermediate AMD is one of the main situations in which AREDS2 may be recommended.
• Late AMD in one eye can also make the formula relevant for protecting the other eye from progression.
• People with no AMD should not assume AREDS2 will prevent the disease.
• People with early AMD should discuss monitoring, lifestyle, diet, and individual risk with an eye-care professional rather than automatically starting high-dose AREDS2 supplements.
• The decision should ideally be based on an eye examination rather than self-diagnosis.

What I would never do is start taking an AREDS2 supplement simply because vision has become blurry. Blurred vision can have many causes, including refractive errors, cataracts, dry eye, retinal disease, diabetes-related eye problems, glaucoma, or other conditions. AREDS2 is intended for a specific disease context, which is why establishing the diagnosis first is so important.

Does AREDS2 Prevent Macular Degeneration?

This is probably the biggest misconception I encounter. AREDS2 has not been shown to prevent AMD from developing in a person who does not already have the relevant stage of the disease. The National Eye Institute explicitly states that nutritional supplements cannot prevent AMD and that the AREDS/AREDS2 formulas are primarily intended to delay progression from intermediate toward advanced AMD in appropriate patients.

That distinction between prevention and progression is more than semantics. Imagine someone with completely healthy maculas taking AREDS2 for decades because they assume it functions like a protective vaccine against AMD. The available clinical evidence does not establish that benefit. By contrast, a person who has already developed intermediate AMD may have a substantially different risk profile, and that is where the evidence supporting AREDS-type supplementation becomes more relevant.

I therefore think the most responsible way to describe AREDS2 is as a risk-reduction strategy for disease progression in selected people with AMD, not as a universal anti-aging vitamin for the eyes. Even in the appropriate population, it does not guarantee that advanced AMD will never develop. Risk reduction is not the same as complete protection, and people taking AREDS2 still need ongoing retinal examinations.

AREDS2, Cataracts, and Other Eye Problems

Because AREDS2 is marketed so heavily around eye health, it can be easy to assume that the formula treats almost every major age-related eye condition. The research does not support such a broad conclusion. One important example is cataract. Although AREDS and AREDS2 investigated cataract-related outcomes, the evidence did not establish AREDS2 as a general treatment for preventing cataracts.

In the AREDS2 cataract analysis, lutein and zeaxanthin supplementation did not significantly reduce the overall likelihood of cataract surgery in the primary analysis. There were observations suggesting possible differences among participants with particularly low dietary lutein and zeaxanthin intake, but those findings do not transform AREDS2 into a proven cataract treatment for the general population.

The same principle applies to conditions such as glaucoma, diabetic retinopathy, ordinary eye strain, presbyopia, and refractive errors. These problems have different causes and treatments. AREDS2 should not be used as a substitute for diagnosis or appropriate medical treatment simply because it contains nutrients associated with eye health.

The Safety Questions I Would Consider Before Taking AREDS2

One thing I appreciate about AREDS2 research is that it reminds us that “vitamin” does not automatically mean “risk-free.” The amounts used in an AREDS2 formula are considerably higher than normal dietary requirements for several nutrients. Anyone taking prescription medications, multiple supplements, or treatment for chronic health conditions should therefore make sure their doctor, ophthalmologist, or pharmacist knows what they are using.

Vitamin E is one example. The NIH Office of Dietary Supplements notes that supplemental vitamin E can interact with anticoagulant and antiplatelet medications and may increase bleeding risk at high intakes. That does not mean everyone taking AREDS2 will experience bleeding. It does mean that someone using medications such as warfarin or other therapies affecting clotting should not treat a high-dose vitamin formula as medically irrelevant.

Zinc also deserves attention. The standard AREDS2 formulation contains more zinc than the usual adult tolerable upper intake level established for routine dietary intake, although upper limits are not intended to prohibit medically supervised therapeutic use. High-dose zinc over time can interfere with copper absorption, which helps explain why copper is deliberately included in the AREDS formulations. Zinc may also interact with certain antibiotics and medications such as penicillamine.

Why Beta-Carotene Was Removed From AREDS2

The replacement of beta-carotene is one of the most important differences between AREDS and AREDS2. The original AREDS formula included 15 mg of beta-carotene. However, evidence from other research raised concern about supplemental beta-carotene and lung-cancer risk in smokers, making the ingredient undesirable for a supplement likely to be used by older adults, including people with current or previous smoking histories.

The AREDS2 trial itself reinforced the concern. More lung cancers occurred among participants assigned to beta-carotene than among those who did not receive it, and most cases occurred in former smokers. Lutein and zeaxanthin therefore provided a much more practical carotenoid alternative.

For that reason, I would pay close attention to the label if I were shopping for an AREDS supplement today. Someone who currently smokes or previously smoked should specifically avoid an older AREDS formulation containing beta-carotene unless a qualified clinician has provided a compelling individualized reason otherwise. The modern AREDS2 approach is designed without beta-carotene.

How Eye Supplements Can Help—and Where Retina Clear Fits

I do think eye supplements can have a reasonable place in an overall eye-health strategy, but I separate two different concepts. One category consists of disease-specific nutritional formulations supported by clinical trials, with AREDS2 being the clearest example for intermediate AMD and certain cases involving late AMD. The other category consists of general eye-health supplements that may provide nutrients such as lutein, zeaxanthin, vitamins, minerals, plant extracts, or antioxidants without necessarily reproducing the AREDS2 formulation.

A supplement such as Retina Clear is best evaluated in that second context unless its current Supplement Facts label exactly matches a validated AREDS2 formula and the product is specifically being chosen for that purpose. I would never assume that a supplement is an AREDS2 substitute merely because it contains ingredients associated with retinal health. Lutein in a formula does not automatically make the entire product clinically equivalent to AREDS2, just as adding zinc to a multivitamin does not recreate the dosage and evidence behind the original AREDS trials.

When I assess an eye-support supplement such as Retina Clear, these are the questions I consider most useful:

• Does the label disclose the exact amount of lutein and zeaxanthin rather than hiding them inside a proprietary blend?
• Does the product make realistic nutritional-support claims rather than promising to reverse serious eye disease?
• If I need AREDS2 for diagnosed AMD, does the label actually match the evidence-based formulation recommended by my eye-care professional?
• Am I already taking another multivitamin or supplement that could cause overlapping vitamin or mineral intake?
• Is there evidence for the finished formula, or are the claims based mainly on studies of individual ingredients?

I also make an important distinction between ingredient evidence and product evidence. Lutein and zeaxanthin have meaningful research behind them, including their role in macular pigment and their use in AREDS2. That does not mean every commercial formula containing those ingredients has been clinically proven to prevent vision loss. For me, that is the fairest way to discuss supplements such as Retina Clear: they may provide eye-related nutrients, but they should not be presented as interchangeable with a clinically studied AREDS2 regimen unless the formula and intended use genuinely match the evidence.

Can I Get the Same Nutrients From Food?

I am a strong believer that supplements and food should not be framed as rivals. A nutritious diet provides far more than isolated vitamins and minerals. Dark leafy vegetables such as spinach and kale can provide lutein and zeaxanthin, while fruits, vegetables, nuts, seeds, legumes, seafood, and other nutrient-dense foods contribute antioxidants, minerals, fiber, healthy fats, and many other compounds that support overall health.

However, the AREDS2 formula contains nutrient amounts that are difficult to reproduce consistently from food alone. The National Eye Institute specifically notes that diet alone does not typically supply the same high levels of antioxidants and zinc that were used in AREDS and AREDS2. That is why someone with the appropriate stage of AMD should not assume that eating a serving of spinach is nutritionally equivalent to taking a medically recommended AREDS2 supplement.

At the same time, I would never view AREDS2 as permission to ignore diet. Research into AMD continues to support the broader importance of healthy dietary patterns, avoiding smoking, managing cardiovascular risk factors, remaining physically active, and attending regular eye examinations. A supplement can address one narrow nutritional strategy, while lifestyle influences health through many pathways that a capsule cannot reproduce.

Why Regular Eye Examinations Still Matter

One limitation of discussing AREDS2 online is that readers may understand the formula long before they understand their own AMD stage. Yet the stage is precisely what determines whether AREDS2 is likely to be relevant. Early, intermediate, geographic atrophy, and neovascular AMD are not interchangeable diagnoses, and retinal imaging can reveal changes that someone may not notice through symptoms alone.

An ophthalmologist or optometrist can examine the retina, identify drusen and pigment changes, and determine whether specialist referral or additional testing is appropriate. When AMD is present, retinal imaging techniques such as optical coherence tomography can give clinicians considerably more information than a home vision test alone. Knowing that AREDS2 exists is useful; knowing whether your eyes actually fit the studied population is much more useful.

Regular follow-up is also important because supplements do not replace medical therapies. Wet or neovascular AMD, for example, may require treatments such as intravitreal anti-VEGF injections. Someone noticing new distortion, a dark or blank central area, rapidly changing central vision, or other sudden visual changes should seek professional evaluation rather than increasing supplement intake and hoping the symptoms improve.

Newer Research Has Added More Nuance to AREDS2

One reason I continue to view AREDS2 as an interesting area of research is that investigators have kept analyzing participants long after the original trial results were published. Long-term analyses of AREDS data have reinforced that the benefits of the antioxidant-and-zinc strategy for appropriate AMD patients can persist over extended periods.

More recently, researchers have also investigated whether AREDS-type supplements might influence the pattern of geographic atrophy, an advanced form of dry AMD. A 2024 analysis using data from AREDS and AREDS2 found evidence suggesting that antioxidant supplementation could slow the progression of geographic atrophy toward the central foveal region, although this was a post hoc analysis rather than the original primary endpoint of the trials.

I find research like this promising, but I also think it needs to be described accurately. A post hoc analysis can generate useful clinical insights without carrying exactly the same evidentiary weight as a trial prospectively designed around that specific outcome. AREDS2 remains relevant, but it is not the final chapter in nutritional research on retinal disease.

Common Mistakes I Would Avoid With AREDS2

The first mistake I would avoid is purchasing an AREDS2 supplement solely because I am over 50. Age certainly increases the risk of AMD, but age by itself does not establish that someone needs the high-dose AREDS2 formula. A retinal examination provides far more useful information than a birthday.

The second mistake is doubling up on supplements without checking the total intake. Someone might take an AREDS2 product, a general multivitamin, a separate zinc tablet, vitamin E, and another eye-health formula at the same time. That can result in unexpectedly high nutrient intake. Before combining supplements, I would write down everything being used and show the list to a healthcare professional or pharmacist.

The third mistake is expecting noticeable visual improvement within a few days or weeks. AREDS2 is not designed as a rapid “vision booster.” Its clinical purpose is reducing the risk of disease progression over time in selected AMD patients. A person can take AREDS2 appropriately without suddenly noticing brighter colors or sharper reading vision. The benefit being pursued is largely about long-term risk rather than an immediate sensation.

My Practical Approach to Choosing an AREDS2 Product

If my eye-care professional told me that AREDS2 was appropriate for my AMD stage, my first step would be comparing the Supplement Facts panel with the established formula. I would look specifically for vitamin C, vitamin E, lutein, zeaxanthin, zinc, and copper in the appropriate amounts. I would also confirm that beta-carotene is absent, especially if I had ever smoked.

I would then check whether taking the product could overlap with medications or other supplements already in my routine. This part is easy to underestimate because supplements are often sold without the psychological weight we associate with prescription medication. Yet nutrients taken in therapeutic quantities can still produce interactions and side effects.

Finally, I would choose a reputable manufacturer that clearly identifies ingredient amounts rather than relying heavily on vague phrases such as “advanced retinal complex.” An eye supplement does not become more evidence-based because the packaging looks medical. Transparency, appropriate dosing, realistic claims, and alignment with the clinical evidence matter far more than branding.

What AREDS2 Cannot Do

Even after going through all of the positive evidence, I think it is equally important to establish realistic expectations. AREDS2 does not restore retinal tissue that has already been permanently damaged. It does not cure macular degeneration, guarantee that AMD will never progress, or replace medical treatment for advanced forms of the disease.

It also cannot correct refractive errors such as nearsightedness, farsightedness, presbyopia, or astigmatism. If someone needs glasses to read clearly, an AREDS2 supplement is not going to reshape the cornea or change the optical power of the eye. Similarly, it should not be promoted as a treatment for cataracts, glaucoma, retinal detachment, or other unrelated eye diseases.

Where AREDS2 becomes genuinely meaningful is much narrower and more scientifically defensible: it provides a studied nutritional strategy that can lower the risk of progression to advanced AMD in certain people who already have clinically significant AMD. I find that more impressive than exaggerated marketing because it is a real, measurable clinical benefit supported by long-term research.

My Final Thoughts on AREDS2

After reviewing the clinical evidence, I see AREDS2 as one of the better examples of how nutrition can have a legitimate role in medicine without becoming a cure-all. The original AREDS study demonstrated that high-dose antioxidants and zinc could help reduce progression toward advanced AMD in people at substantial risk, and AREDS2 refined the formula by replacing beta-carotene with lutein and zeaxanthin.

The biggest lesson I would want readers to remember is that AREDS2 is about using the right supplement for the right person. Someone with intermediate AMD may have a good evidence-based reason to use it. Someone with completely healthy eyes does not automatically gain the same benefit by taking the formula “just in case.” That difference is why I strongly favor discussing AREDS2 with an ophthalmologist or another qualified eye-care professional after the retina has actually been examined.

I also believe there is room for broader eye-health supplements, including products such as Retina Clear, as long as expectations remain grounded. Nutrients such as lutein and zeaxanthin are scientifically interesting and biologically relevant to the macula, but a supplement containing eye-related nutrients should not automatically be treated as an AREDS2 replacement or an AMD treatment. For me, understanding that distinction is one of the best ways to make smarter decisions in a supplement market that often blurs the line between nutritional support and medical evidence.

Disclaimer

This article is intended for educational and informational purposes only. It is based on publicly available medical research and guidance from organizations including the U.S. National Eye Institute and National Institutes of Health. Nothing in this article should be interpreted as medical advice, diagnosis, treatment, or a recommendation to begin or discontinue a particular supplement.

AREDS2 supplements contain relatively high amounts of several nutrients and may not be appropriate for everyone. Individual medical history, AMD stage, medications, smoking history, nutritional intake, and other supplements can all influence whether an AREDS2 formula is appropriate. Anyone considering AREDS2 should discuss it with an ophthalmologist, optometrist, physician, pharmacist, or other qualified healthcare professional, particularly when prescription medications or existing health conditions are involved.

Any discussion of Retina Clear or other commercial supplements is provided only to explain how general eye-health supplements differ from the clinically studied AREDS2 approach. This article does not claim that Retina Clear prevents, treats, reverses, or cures macular degeneration or any other eye disease. Sudden vision loss, new distortion, flashes of light, a sudden increase in floaters, a curtain-like shadow, severe eye pain, or other abrupt changes in vision require prompt professional medical evaluation.

References

2. National Eye Institute — AREDS/AREDS2 Clinical Trials.
Official overview of the original AREDS and AREDS2 studies, including the compositions of the studied formulas and the replacement of beta-carotene with lutein and zeaxanthin.
National Eye Institute: About AREDS and AREDS2

3. National Eye Institute — AREDS2 Supplements for Age-Related Macular Degeneration.
Patient-focused evidence-based guidance explaining when AREDS2 supplements may be appropriate and why professional guidance is recommended.
National Eye Institute: Nutritional Supplements for AMD

4. Age-Related Eye Disease Study 2 Research Group. Lutein + Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular Degeneration. JAMA. 2013.
The landmark randomized AREDS2 clinical trial involving 4,203 participants and evaluating lutein, zeaxanthin, omega-3 fatty acids, beta-carotene removal, and alternative zinc levels.
PubMed: AREDS2 Randomized Clinical Trial

5. Chew EY, et al. The Age-Related Eye Disease Study 2: Study Design and Baseline Characteristics. Ophthalmology.
Peer-reviewed description of the AREDS2 study design, participant population, treatment groups, nutrient doses, and primary clinical objectives.
PubMed: AREDS2 Study Design and Baseline Characteristics

6. Age-Related Eye Disease Study Research Group — The Age-Related Eye Disease Study: Results of the Clinical Trial.
Summary of the original AREDS findings showing that the antioxidant-and-zinc combination reduced progression to advanced AMD among participants at high risk.
PubMed: Original AREDS Clinical Trial Results

7. Chew EY, et al. Long-Term Effects of Vitamins C and E, Beta-Carotene, and Zinc on Age-Related Macular Degeneration: AREDS Report No. 35.
Long-term follow-up of AREDS participants evaluating the persistence of the nutritional intervention’s effects on progression toward advanced AMD.
PubMed: AREDS Report No. 35

8. National Institutes of Health Office f Dietary Supplements — Zinc: Health Professional Fact Sheet.
Authoritative information covering zinc requirements, tolerable upper intake levels, excessive intake, copper interactions, and interactions with medications.
NIH Office of Dietary Supplements: Zinc Fact Sheet

9. National Institutes of Health Office of Dietary Supplements — Vitamin E: Health Professional Fact Sheet.
Evidence-based information on vitamin E intake, supplementation safety, anticoagulant and antiplatelet interactions, and other health considerations.
NIH Office of Dietary Supplements: Vitamin E Fact Sheet

10. Oral Antioxidant and Lutein/Zeaxanthin Supplements and Geographic Atrophy Progression in AMD.
A more recent analysis of AREDS and AREDS2 data investigating whether oral micronutrient supplementation may influence geographic atrophy progression toward the fovea.
PubMed: Geographic Atrophy and AREDS Supplementation